Since the beginning of this year, Novartis, a leading multinational pharmaceutical company, has made continuous moves, first announcing the adjustment of the company's global business framework, planning to lay off 8,000 employees, and then integrating the two business units of pharmaceuticals and oncology into one innovative drug department, while merging
the technology operations, customers and technical departments.
In the second half of the year, Novartis has not stopped
.
Recently, Novartis announced that it will lay off 1,400 jobs in Switzerland in the future, about half of which will be leadership and management positions
.
At a media event in Zurich, Novartis Switzerland said that the first batch of people to receive a termination notice will be notified
in the coming weeks.
However, due to employee contracts, the layoffs in Switzerland may not take effect
until the summer of 2023.
In addition to the layoffs, Novartis recently said it plans to close its Sandoz generic drug plant in Wilson, North Carolina, around the end of 2023, citing the inability to fully utilize the capacity
of the U.
S.
plant.
According to public statistics, Novartis' Sandoz generic drug factory in Wilson, North Carolina, currently has 246 employees, mainly engaged in the sales of oral solid preparation products in the United States and Canada
.
As early as the second half of 2021, it was reported that Novartis may divesce its generic drug division Sandoz in the process of promoting the divestiture of its generic drug and consumer business across the industry
.
According to other media reports, Sweden's EQT and Germany's Struengmann family are considering a joint action to buy the generic drug company
for $21.
6 billion.
In late August 2022, Novartis announced a complete divestiture of its pharmaceutical division, Sandos, to list on the Swiss exchange SIX Swiss Exchange and implement the American Depositary Securities (ADR) program in the
United States.
The final decision will be made
by the end of 2022.
And Novartis itself will focus on innovative medicines
.
Layoffs, integration and restructuring can be said to be Novartis' proactive decisions
under the transformation of the global pharmaceutical market.
According to the financial report, in the second quarter of 2022, Novartis' earnings and sales declined, of which sales fell to $12.
78 billion from $12.
96 billion in the same period last year, and core operating profit and net profit fell to $4.
27 billion and $1.
69 billion, respectively, from $4.
35 billion and $2.
89 billion in the same period of the previous year
.
While doing subtraction, Novartis also does some "addition"
.
On September 12, Novartis announced that it will invest $300 million in next-generation biotherapies including API and pharmaceutical product development, involving plants
in Switzerland, Slovenia and Austria.
In addition, Novartis plans to invest $100 million in the Novartis St.
John's campus in Basel, Switzerland, to build a biologics center to complement the existing NIBR Biologics Center
.
As the business adjusts, changes in Novartis' senior management continue
.
For example, Novartis said it would appoint Merck executive Fiona Marshall as director of Novartis' Biomedical Institute to replace Jay Bradner, who is stepping down after 7 years as the drugmaker's head of research
.
Marshall's appointment will take effect
on November 1 this year.
On August 24, Sandoz announced to employees that Sandoz Greater China President Hui Ming Yu will leave Sandoz for external career development opportunities until September 28, 2022
.
In June, Novartis announced that the head of Novartis' innovative drugs in the field of cancer treatment in China will be Zhu Jiakang, who previously served as the head
of AstraZeneca's lung cancer treatment and tumor immunotherapy business unit.
In addition, Ying Zhang, President of Novartis Pharma China, has been appointed President and Managing Director of Innovative Pharma China
.
In addition to China, Novartis has also appointed heads of
innovative medicines in multiple regions, including Asia Pacific, the Middle East and Africa, Japan, Latin America and Canada.
![3-bromodibenzo[b,d]thiophene](https://file.echemi.com/fileManage/upload/cas/822/bb4496d0-decc-11eb-89d6-0255ac100033.png)
